On August 10, 2020 Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), reported that Bristol Myers Squibb ("BMS") has licensed its fourth TriNKET immunotherapy drug candidate from Dragonfly (Press release, Dragonfly Therapeutics, AUG 10, 2020, View Source [SID1234563377]). Since the original 2017 collaboration focusing on hematology malignancies, the companies have agreed two additional collaborations across solid tumors, and autoimmune disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are impressed with the quality of candidates developed using Dragonfly’s TriNKET technology," said Rupert Vessey, FRCP, DPhil, President of Research and Early Development, Bristol Myers Squibb. "In just three years, Dragonfly delivered four drug candidates to BMS, a remarkable pace of development. During that time, we have assessed Dragonfly’s TriNKET drug candidates in both cancer and autoimmune indications, and have built three collaborations together. We continue to be encouraged by the potential treatment options for patients offered by harnessing the power of NK cells."

"We have had a very productive collaboration with BMS and are pleased with both the speed of our development efforts and the continuing validation of our platform that this opt-in decision by BMS represents," said Dragonfly CEO Bill Haney. "As we advance our internal programs, including our clinical stage TriNKET DF-1001 and IL12 cytokine DF-6002, we look forward to strong continued collaboration with BMS to bring potential new NK-cell based treatment options to patients with cancer, autoimmune disease, and neurological conditions."

On August 10, 2020 China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, reported that the Company plans to release its second quarter 2020 financial results on Monday, August 17, 2020 after the market closes (Press release, China Biologic Products, AUG 10, 2020, View Source [SID1234563376]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s management will hold a conference call at 7:30 a.m. ET on Tuesday, August 18, 2020, which is 7:30 p.m. Beijing Time on August 18, 2020, to discuss second quarter 2020 results. Listeners may access the call by dialing:

US:

1 888 346 8982

International:

1 412 902 4272

Hong Kong:

800 905945

Mainland China:

4001 201203

A telephone replay will be available one hour after the conclusion of the conference call through August 25, 2020. The dial-in details are:

US:

1 877 344 7529

International:

1 412 317 0088

Passcode:

10147239

A live and archived webcast of the conference call will be available through the Company’s investor relations website at View Source

On August 10, 2020 VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, reported the underwriters of its previously announced public offering of common stock exercised and closed their over-allotment option, resulting in VistaGen’s receipt of additional gross proceeds of approximately $1.79 million from the offering for the issuance of 2,243,250 shares (Press release, VistaGen Therapeutics, AUG 10, 2020, View Source [SID1234563375]). Including the closing of the over-allotment option, VistaGen issued 17,868,250 shares of common stock in the underwritten public offering and, before underwriting discounts and commissions and offering expenses, received gross proceeds of approximately $14.29 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VistaGen currently intends to use the net proceeds from the offering for the continued development of its CNS pipeline programs, general research and development, working capital and general corporate purposes.

Maxim Group LLC acted as sole book-running manager for the offering.

The securities described above were offered by VistaGen pursuant to an effective shelf registration statement on Form S-3 (File No. 333-234025), previously filed with the U.S. Securities and Exchange Commission (SEC) on September 30, 2019 and declared effective on October 7, 2019. The securities were offered by means of a prospectus supplement and accompanying prospectus, forming part of the registration statement. The prospectus supplement and accompanying prospectus relating to this public offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting Maxim Group LLC, at 405 Lexington Avenue, 2nd Floor, New York, NY 10174, Attention: Prospectus Department, by telephone at (212) 895-3745, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On August 10, 2020 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jeff Ajer, Executive Vice President and Chief Commercial Officer, and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 10:55am ET and Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Executive Vice President, Chief Financial Officer, will participate in the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 1:00pm ET (Press release, BioMarin, AUG 10, 2020, View Source [SID1234563374]). An audio webcast of the presentations will be available live. You can access the webcast at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 10, 2020 Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, reported the full availability of ELIGARD (leuprolide acetate) for injectable suspension in all doses for patients undergoing palliative treatment for advanced prostate cancer (Press release, Tolmar Pharmaceuticals, AUG 10, 2020, View Source [SID1234563373]). The company confirmed the complete inventory of product supply and also announced a production increase in response to reports of a shortage in the United States for a different leuprolide acetate injection product used in the palliative treatment for advanced prostate cancer. Tolmar has a demonstrated record of providing consistent supply of ELIGARD in the U.S. and globally across approximately 89 countries, with no shortages to date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 24, 2020 and re-verified on August 3, 2020, the U.S. Food and Drug Administration (FDA) listed the Lupron Depot, 3 months, 22.5 mg PDS Kit and 6 months, 45 mg PDS Kit as not available and on backorder in its database of Current and Resolved Drug Shortages and Discontinuations Reported to FDA. The listing indicates the estimated duration of this shortage is currently unknown.

"Tolmar is pleased to step up production in our state-of-the-art cGMP facilities to help ensure that advanced prostate cancer patients across the U.S. won’t miss a single injection in their treatment plan," said Anil D’Souza, Chief Executive Officer, Tolmar. "ELIGARD has always been manufactured to the highest quality standards in our Northern Colorado plants, and we are able to fill any short or long-term gaps in the supply of this drug for those who need it."

ELIGARD (leuprolide acetate) for injectable suspension, an FDA-approved palliative treatment for advanced prostate cancer, is given by subcutaneous injection. It is a form of androgen deprivation therapy, which is the standard of care for the treatment of advanced prostate cancer. A luteinizing hormone-releasing hormone (LHRH) agonist, ELIGARD reduces circulating testosterone to castration levels to inhibit the growth of cancer cells. It may be administered monthly or in three, four or six-month controlled-release doses. All doses are in inventory.

"During the global COVID-19 pandemic, cancer patients, providers and others in the urology and uro-oncology community should not have an added concern about the supply of a vital medication," continued Mr. D’Souza. "Tolmar has a full inventory of API and the other components of ELIGARD, and the capacity to manufacture sufficient supply of the drug for those who need it at this time."

For more information about product availability or any questions about reported leuprolide acetate product shortages in the U.S. market, please contact Tolmar at 1-877-ELIGARD (1-877-354-4273).